Cellectis (PA:ALCLS) — Market Cap & Net Worth
Market Cap & Net Worth: Cellectis (ALCLS)
Cellectis (PA:ALCLS) has a market capitalization of $235.25 Million (€201.22 Million) as of June 16, 2026. Listed on the PA stock exchange, this France-based company holds position #16029 globally and #234 in its home market, demonstrating a 5.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellectis's stock price €2.77 by its total outstanding shares 72590994 (72.59 Million). Review ALCLS total debt and obligations to assess the company's total debt and financial obligations.
Cellectis Market Cap History: 2015 to 2026
Cellectis's market capitalization history from 2015 to 2026. Data shows change from $2.37 Billion to $235.25 Million (-18.25% CAGR).
Index Memberships
Cellectis is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$40.75 Billion | 0.58% | #17 of 34 |
Weight: Cellectis's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellectis Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellectis's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.69x
Cellectis's market cap is 4.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $42.58 Million | -$63.92 Million | 32.30x | N/A |
| 2017 | $2.02 Billion | $25.19 Million | -$99.37 Million | 80.32x | N/A |
| 2018 | $1.28 Billion | $12.73 Million | -$78.69 Million | 100.53x | N/A |
| 2019 | $1.33 Billion | $15.19 Million | -$90.69 Million | 87.60x | N/A |
| 2020 | $2.07 Billion | $73.95 Million | -$72.57 Million | 28.00x | N/A |
| 2021 | $631.41 Million | $73.95 Million | -$86.28 Million | 8.54x | N/A |
| 2022 | $168.63 Million | $19.17 Million | -$98.69 Million | 8.80x | N/A |
| 2023 | $234.57 Million | $755.00K | -$101.06 Million | 310.69x | N/A |
| 2024 | $138.33 Million | $41.51 Million | -$36.76 Million | 3.33x | N/A |
| 2025 | $356.01 Million | $75.92 Million | -$70.35 Million | 4.69x | N/A |
Competitor Companies of ALCLS by Market Capitalization
Companies near Cellectis in the global market cap rankings as of June 16, 2026.
Key companies related to Cellectis by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Cellectis Historical Marketcap From 2015 to 2026
Between 2015 and today, Cellectis's market cap moved from $2.37 Billion to $ 235.25 Million, with a yearly change of -18.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €235.25 Million | -33.92% |
| 2025 | €356.01 Million | +157.36% |
| 2024 | €138.33 Million | -41.03% |
| 2023 | €234.57 Million | +39.10% |
| 2022 | €168.63 Million | -73.29% |
| 2021 | €631.41 Million | -69.51% |
| 2020 | €2.07 Billion | +55.61% |
| 2019 | €1.33 Billion | +3.98% |
| 2018 | €1.28 Billion | -36.74% |
| 2017 | €2.02 Billion | +47.07% |
| 2016 | €1.38 Billion | -41.94% |
| 2015 | €2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Cellectis was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $235.25 Million USD |
| MoneyControl | $235.25 Million USD |
| MarketWatch | $235.25 Million USD |
| marketcap.company | $235.25 Million USD |
| Reuters | $235.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more